Study Links Wegovy Use to Increased Risk of Sudden Sight Loss
In Brief
A study found Wegovy users have nearly five times the risk of 'eye stroke' compared to Ozempic users.
Key Facts
- A large-scale study found Wegovy users have nearly five times the risk of sudden sight loss compared to Ozempic users.
- The condition, referred to as 'eye stroke', involves reduced blood flow to the optic nerve.
- Both Wegovy and Ozempic contain the active ingredient semaglutide.
- The study's author suggested that 'eye strokes' are likely a side-effect of semaglutide.
- GLP-1 RA medicines like semaglutide and tirzepetide are used to reduce blood sugar, slow digestion, and reduce appetite.
What Happened
A study reported that patients taking Wegovy have a significantly higher risk of sudden sight loss, known as 'eye stroke', compared to those using Ozempic. Both drugs contain semaglutide, a GLP-1 receptor agonist.
Why It Matters
The findings raise concerns about the safety profile of popular weight loss and diabetes medications containing semaglutide. Patients and healthcare providers may need to weigh the benefits and potential risks when considering these treatments.
What's Next
Further research may be conducted to confirm these findings and clarify the mechanisms involved. Regulatory agencies and medical professionals may review current guidance on prescribing semaglutide-based medications.
Sources
- The Independent — Weight loss jab linked to high risk of ‘eye stroke’(1d ago)
- The Guardian — Wegovy users have five times greater risk of sudden sight loss than Ozempic users, study finds(1d ago)